BerGenBio AS

145 articles about BerGenBio AS

• BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

  2/7/2024

  BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented "Investigating the effects of AXL inhibition during respiratory viral infections" during the 6th Forum on Respiratory Infections in Glasgow, Scotland.

• BerGenBio Reports Third Quarter 2023 Financial Results

  11/14/2023

  BerGenBio ASA announced financial results for the quarter ended September 30, 2023, and provided a business update.

• BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

  11/6/2023

  BerGenBio ASA announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD's anti-PD-1 therapy, KEYTRUDA® in second line Non-Small Cell Lung Cancer patients was presented on November 4th at the 2023 Society of Immunotherapy of Cancer Annual Meeting.

• BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

  10/31/2023

  BerGenBio ASA today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.

• New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

  10/23/2023

  BerGenBio ASA announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer were presented during the European Society of Clinical Oncologists Annual Meeting 2023.

• Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

  10/16/2023

  BerGenBio ASA announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists Annual Meeting 2023, to be held October 20-24 in Madrid.

• BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

  8/22/2023

  BerGenBio ASA announced that additional clinical data of bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small Cell Lung Cancer have been recently published and accepted for presentation at two upcoming international oncology conferences.

• BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

  4/18/2023

  BerGenBio ASA announced that it presented data linking AXL activation to STK11 loss of function in Non-Small Cell Lung Cancer in an abstract titled, AXL as a Therapeutic Target in STK11 mutant NSCLC, at the American Association for Cancer Research Annual Meeting 2023.

• BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

  3/9/2023

  BerGenBio ASA announced the first patient was dosed in a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line Non-Small Cell Lung Cancer patients harboring STK11 mutations.

• BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

  2/16/2023

  BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the fourth quarter ended December 31, 2022, and provided a business update.

• BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

  2/15/2023

  BerGenBio ASA (OSE: BGBIO) today announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinib in combination with MSD's anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC) patients.

• BerGenBio Announces the Establishment of Oncology Scientific Advisory Board

  2/2/2023

  BerGenBio ASA announced the formation of a scientific advisory board consisting of four world-renowned non-small cell lung cancer experts from top oncology centers around the globe to enhance the development of bemcentinib for the treatment of NSCLC patients with STK11 mutations.

• BerGenBio reports third quarter 2022 financial results and provides business update

  11/15/2022

  BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the third quarter ended September 30, 2022 and provided a business update.

• BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS

  10/25/2022

  BerGenBio ASA and Meteva AS announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.

• BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

  10/11/2022

  BerGenBio ASA announced the initiation of a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line Non-Small Cell Lung Cancer patients harboring STK11 mutations.

• BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS

  9/27/2022

  BerGenBio ASA announced today that the first patient has been included in a study of BerGenBio's oral, highly selective AXL inhibitor, bemcentinib.

• BerGenBio reports second quarter and half year 2022 financial results and provides business update

  8/23/2022

  BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the second quarter and half year ended June 30, 2022 and provided a business update.

• Bergenbio Announces Launch Of Business Strategy Focused On NSCLC And Covid-19

  5/4/2022

  BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces an update on its business strategy.

• Bergenbio Announces Complete Data Analysis Of Accord2 Phase II Bemcentinib Study In Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

  4/26/2022

  BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced that a complete data analysis of a randomized phase II study of bemcentinib in combination with standard of care therapy, ACCORD2, in hospitalized COVID-19 patients confirms that the primary efficacy endpoint was met.

• 

  Clinical Catch-Up: January 24 – January 28

  1/31/2022

  Clinical trial news definitely picked up this final week of January. Here’s a look.